Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia
Key facts
- Who runs it
- Peking Union Medical College Hospital
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 31 people, planned
- Started
- Nov 2026
- Expected to end
- Dec 2029
- Type of study
- Interventional
- Treatments tested
- Gecacitinib
- Luspatercept
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (22)Hide the full registry criteria
Who can take part
- Age 18 years or older
- Confirmed primary myelofibrosis according to the 2016 World Health Organization diagnostic criteria, or post-polycythemia vera or post-essential thrombocythemia myelofibrosis according to the International Working Group for Myeloproliferative Neoplasms Research and Treatment diagnostic criteria
- Intermediate-2 or high-risk disease according to the Dynamic International Prognostic Scoring System (DIPSS) or DIPSS-plus, or intermediate-1-risk disease with hepatosplenomegaly that is unresponsive to existing treatment and requires treatment
- No previous treatment with a Janus kinase inhibitor
- Discontinuation of other myelofibrosis treatments, such as interferon or hydroxyurea, immunosuppressants, corticosteroids, and growth factors such as erythropoietin, for at least 2 weeks or 6 half-lives before study treatment
- Splenomegaly, with the spleen palpable 5 cm below the left costal margin
- Hemoglobin below 100 g/L, with or without red blood cell transfusion dependence
- Platelet count of at least 75 × 10\^9/L
- Absolute neutrophil count of at least 1.0 × 10\^9/L
- Peripheral blood blasts of 10% or less
- Eastern Cooperative Oncology Group performance status of 0-2 and a life expectancy of more than 6 months
- Ability to independently provide written informed consent
Who cannot take part
- Previous splenectomy
- Previous treatment with any transforming growth factor-beta ligand inhibitor
- Clinically significant anemia associated with iron, vitamin B12, or folate deficiency; autoimmune or hereditary hemolytic anemia; gastrointestinal bleeding; or thalassemia
- Active infection
- A history of malignancy within the previous 5 years, except for cured basal cell carcinoma of the skin or cervical carcinoma in situ
- Suspected hypersensitivity to gecacitinib, luspatercept, or drugs of the same class
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study
- Other serious conditions that, in the investigator's judgment, may affect participant safety or compliance, including:; Uncontrolled diabetes mellitus, with blood glucose above 250 mg/dL or 13.9 mmol/L; Hypertension that cannot be controlled to a systolic blood pressure below 160 mmHg and a diastolic blood pressure below 100 mmHg despite combination antihypertensive treatment; Peripheral neuropathy of grade 2 or higher according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0
- Significant hepatic or renal dysfunction, or dysfunction of another major organ
- Pregnancy or breastfeeding, women planning pregnancy during the study, or men with near-term plans to father a child
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Myelofibrosis
About the trial
What the trial wants to find out
This single-center, prospective, single-arm study aims to evaluate the efficacy and safety of gecacitinib combined with luspatercept in patients with myelofibrosis and anemia who have not previously received a Janus kinase inhibitor. Participants will receive oral gecacitinib and subcutaneous luspatercept.
The group in the trial
- Gecacitinib + LuspaterceptTreatment being tested
gecacitinib 100 mg orally twice daily, combined with luspatercept at an initial dose of 1.0 mg/kg subcutaneously every 3 weeks
Treatment: Gecacitinib and Luspatercept
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Gecacitinib Combined With Luspatercept in Patients With Myelofibrosis and Anemia: A Single-center, Prospective, Single-arm Study
- Criteria questions
- Built from NCT07938580, who can take part
- Record updated
- 16 November 2026